NCT03896516View on ClinicalTrials.gov

Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions
Alcohol Use Disorder
Interventions
OTHER

Placebo

Participants receive Placebo orally twice daily.

DRUG

GLWL-01

GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.

Trial Locations (1)

21224

National Institute on Drug Abuse, Baltimore

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH